Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from 4DMedical Ltd ( (AU:4DX) ) is now available.
4DMedical Limited has received $6.0 million in R&D Tax Incentive credits, bolstering its financial position alongside a $10.0 million strategic investment from Pro Medicus. This positions the company to advance the commercialization of its CT:VQ™ technology and other products. Additionally, a study published in a leading respiratory journal highlights the efficacy of 4DMedical’s XV LVAS® technology in predicting complications in COPD treatment, potentially improving patient outcomes and reducing healthcare burdens.
The most recent analyst rating on (AU:4DX) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
More about 4DMedical Ltd
4DMedical Limited (ASX:4DX) is a global medical technology company specializing in advanced imaging and artificial intelligence for respiratory care. The company offers innovative solutions such as the FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®), CT LVAS™, and the CT:VQ™ solution, which provide enhanced diagnostic capabilities through a Software-as-a-Service (SaaS) model.
Average Trading Volume: 1,740,602
Technical Sentiment Signal: Buy
Current Market Cap: A$265.4M
For a thorough assessment of 4DX stock, go to TipRanks’ Stock Analysis page.